STOCK TITAN

Opaleye Management reports 11.00% stake in Alpha Cognition (ACOG)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Alpha Cognition Inc. amended a Schedule 13G filing to report that Opaleye Management Inc., together with Opaleye, L.P. and James Silverman, beneficially own 2,388,638 common shares, representing 11.00% of the class. The filing states Opaleye, L.P. holds 2,308,638 shares (10.62%), and cites 21,742,104 shares outstanding as reported November 13, 2025.

The Adviser (Opaleye Management Inc.) advises the Fund and Mr. Silverman controls the Adviser; shared voting and dispositive power are reported for the aggregate holdings. Signatures are dated 03/04/2026.

Positive

  • None.

Negative

  • None.

Insights

Opaleye reports an 11.00% beneficial stake with shared voting and dispositive power.

Opaleye Management Inc. and related entities report beneficial ownership of 2,388,638 shares (11.00%) as of this amendment filed in early March 2026. The filing attributes shared voting and dispositive power across the Adviser, the Fund, and James Silverman.

Control relationships are stated: the Adviser manages the Fund and Mr. Silverman exercises control over the Adviser. The excerpt cites an outstanding share base of 21,742,104 shares as of November 13, 2025, which provides ownership context. Cash‑flow treatment and plans for sale are not detailed in the provided excerpt.






03/02/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Adviser and Mr. Silverman may be deemed to beneficially own additional shares held in a Managed Account, beyond the Fund's direct holdings.


SCHEDULE 13G




Comment for Type of Reporting Person: Based on 21,742,104 Common Shares outstanding as reported by Alpha Cognition, Inc. in its Form 10-Q filed with the SEC on November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Adviser and Mr. Silverman may be deemed to beneficially own additional shares held in a Managed Account, beyond the Fund's direct holdings.


SCHEDULE 13G



Opaleye Management Inc.
Signature:/s/ James Silverman
Name/Title:President
Date:03/04/2026
Opaleye, L.P.
Signature:/s/ James Silverman
Name/Title:General Partner
Date:03/04/2026
James Silverman
Signature:/s/ James Silverman
Name/Title:Individually
Date:03/04/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement by and among the reporting persons

FAQ

What stake does Opaleye report in Alpha Cognition (ACOG)?

Opaleye reports beneficial ownership of 2,388,638 Alpha Cognition shares, equal to 11.00% of the class. The figure is disclosed in the Schedule 13G/A amendment signed on 03/04/2026.

How many shares does Opaleye, L.P. hold according to the filing?

The filing lists 2,308,638 shares held by Opaleye, L.P., representing 10.62% of the class. This percentage is tied to the 21,742,104 shares outstanding reported on November 13, 2025.

Who controls the reported holdings in the Schedule 13G/A for ACOG?

The statement says Opaleye Management Inc. is the Adviser to the Fund and James Silverman exercises control over the Adviser. Shared voting and dispositive power are reported across these reporting persons.

Does the filing show whether Opaleye will sell or buy more ACOG shares?

The amendment reports current beneficial ownership and voting power but does not disclose intended purchases or sales. No plan of disposition or transaction timing is specified in the provided excerpt.

What share count basis does the filing use to calculate percentages?

Percentages are calculated using 21,742,104 common shares outstanding, as reported by Alpha Cognition in its Form 10-Q filed with the SEC on November 13, 2025. That outstanding count is cited in the Schedule 13G/A comments.
Alpha Cognition

NASDAQ:ACOG

ACOG Rankings

ACOG Latest News

ACOG Latest SEC Filings

ACOG Stock Data

124.80M
19.26M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
Canada
VANCOUVER